HANGZHOU, China, March 6, 2026 /PRNewswire/ — Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for ...
Summary: Current Alzheimer’s treatments typically require frequent, high-dose infusions of monoclonal antibodies to slow cognitive decline. But researchers have engineered a potentially game-changing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results